NASDAQ:KOD
JPMorgan Upgrades Kodiak Sciences To Neutral, Sees Catalyst-Heavy Period Ahead
Font: Financial Modeling Prep • Aug 14, 2025
JPMorgan upgraded Kodiak Sciences (NASDAQ:KOD) from Underweight to Neutral and set a December 2026 price target of $15.00.
The bank said Kodiak is entering a catalyst-rich period over the next two years, with pivotal trial data expected for tarcocimab, KSI-501, and KSI-101. While acknowledging that valuation is not a barrier to a more positive stance, JPMorgan noted that investor sentiment remains mixed and that clear clinical wins may be required to shift views more favorably.
The firm sees Kodiak shares performing in line with the broader biotech sector until further clarity emerges from these upcoming data releases.
Market Overview
|
SLXN
Silexion Therapeutics Ltd.
|
$0.32
28.18%
|
|
SLND
Southland Holdings, Inc.
|
$0.70
14.75%
|
|
SOAR
Volato Group, Inc.
|
$0.39
22.33%
|
|
SDEV
NovaBay Pharmaceuticals, Inc.
|
$3.27
108.28%
|
|
BKYI
BIO-key International, Inc.
|
$3.12
85.71%
|
|
HYG
iShares iBoxx $ High Yield Corporate Bond ETF
|
$77.36
-0.23%
|
|
NVDA
NVIDIA Corporation
|
$227.21
-0.72%
|
|
CAPS
Capstone Holding Corp.
|
$0.16
-2.20%
|
|
INTC
Intel Corp.
|
$115.93
-0.09%
|
|
NVD
GraniteShares 2x Short NVDA Daily ETF
|
$3.66
1.39%
|
